Straits Times Index
3,316.04 +8.14 (+0.25%) Nikkei
39,093.77 +476.67 (+1.23%) Hang Seng
18,930.02 -265.58 (-1.38%) FTSE 100
8,370.33 -46.12 (-0.55%) Bitcoin USD
69,431.15 -286.70 (-0.41%) CMC Crypto 200
1,515.05 -11.36 (-0.74%)
Innate Pharma S.A. (0EVI.IL)
- Business Wire
Innate Pharma: Clarification Regarding SAR443579 Designation
MARSEILLE, France, May 21, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi, it was mentioned that the molecule received breakthrough designation. This is an error. The molecule has US FDA Fast Track Designation, as communicated before in June 2023.
- Business Wire
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
MARSEILLE, France, May 15, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that four abstracts with Innate’s drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.
- Business Wire
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
MARSEILLE, France, May 14, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the quarter ending March 31, 2024.
